Williams Laura A insider trades
Williams Laura A has filed 30 Form 4s with the SEC that we hold, for Ardelyx, INC. (ARDX) (Chief Patient Officer) and Enliven Therapeutics, Inc. (IMRA) (Director). Across all of them we count 1 purchase worth $1.9K and 36 sales worth $3.3M reported on Form 4. In the last 12 months: 0 purchases ($0) and 13 sales ($1.0M). The largest single trade was a sale of 100,000 shares of Ardelyx, INC. worth $713.0K, dated 2024-06-05. Of 4 sales filed since we began reading the 10b5-1 checkbox, 0 (0%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2022-06-03 and the latest 2026-08-25.
Ardelyx, INC. (ARDX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-08-22 | S, sale reported on Form 4 | 13 | $13 | 2022-08-24 |
| 2022-08-22 | S, sale reported on Form 4 | 1,263 | $1.2K | 2022-08-24 |
| 2022-08-31 | P, purchase reported on Form 4 | 3,000 | $1.9K | 2022-09-01 |
| 2022-11-22 | S, sale reported on Form 4 | 1,193 | $2.3K | 2022-11-23 |
| 2022-11-22 | S, sale reported on Form 4 | 15 | $29 | 2022-11-23 |
| 2022-11-22 | S, sale reported on Form 4 | 33 | $64 | 2022-11-23 |
| 2023-02-21 | S, sale reported on Form 4 | 3,187 | $9.6K | 2023-02-24 |
| 2023-05-23 | S, sale reported on Form 4 | 2,583 | $9.4K | 2023-05-25 |
| 2023-06-27 | S, sale reported on Form 4 | 25,000 | $83.8K | 2023-06-29 |
| 2023-08-21 | S, sale reported on Form 4 | 2,591 | $9.2K | 2023-08-23 |
| 2023-11-15 | S, sale reported on Form 4 | 25,000 | $100.0K | 2023-11-17 |
| 2023-11-20 | S, sale reported on Form 4 | 2,581 | $11.3K | 2023-11-22 |
| 2024-02-20 | S, sale reported on Form 4 | 4,803 | $42.0K | 2024-02-22 |
| 2024-05-03 | S, sale reported on Form 4 | 39,949 | $333.6K | 2024-05-07 |
| 2024-05-21 | S, sale reported on Form 4 | 4,794 | $37.4K | 2024-05-23 |
| 2024-06-05 | S, sale reported on Form 4 | 100,000 | $713.0K | 2024-06-07 |
| 2024-06-05 | S, sale reported on Form 4 | 45,000 | $320.4K | 2024-06-07 |
| 2024-08-20 | S, sale reported on Form 4 | 7,412 | $43.4K | 2024-08-22 |
| 2024-11-20 | S, sale reported on Form 4 | 7,366 | $35.3K | 2024-11-22 |
| 2025-02-20 | S, sale reported on Form 4 | 4,941 | $27.8K | 2025-02-21 |
| 2025-05-20 | S, sale reported on Form 4 | 6,421 | $26.2K | 2025-05-22 |
| 2025-08-21 | S, sale reported on Form 4 | 6,261 | $37.1K | 2025-08-25 |
| 2025-08-26 | S, sale reported on Form 4 | 50,000 | $306.0K | 2025-08-28 |
| 2025-08-26 | S, sale reported on Form 4 | 30,000 | $183.6K | 2025-08-28 |
| 2025-11-21 | S, sale reported on Form 4 | 6,426 | $35.6K | 2025-11-25 |
| 2026-01-08 | S, sale reported on Form 4 | 50,000 | $349.0K | 2026-01-09 |
| 2026-02-20 | S, sale reported on Form 4 | 984 | $5.6K | 2026-02-23 |
| 2026-02-20 | S, sale reported on Form 4 | 7,192 | $42.2K | 2026-02-23 |
| 2026-05-21 | S, sale reported on Form 4 | 1,418 | $8.9K | 2026-05-22 |
| 2026-05-21 | S, sale reported on Form 4 | 1,911 | $12.0K | 2026-05-22 |
| 2026-05-21 | S, sale reported on Form 4 | 1,503 | $9.4K | 2026-05-22 |
| 2026-05-21 | S, sale reported on Form 4 | 2,157 | $13.5K | 2026-05-22 |
| 2026-06-18 | S, sale reported on Form 4 | 81,898 | $490.6K | 2026-06-22 |
| 2026-08-21 | S, sale reported on Form 4 | 3,486 | $13.4K | 2026-08-25 |
| 2026-08-21 | S, sale reported on Form 4 | 3,089 | $11.9K | 2026-08-25 |
| 2026-08-21 | S, sale reported on Form 4 | 2,430 | $9.4K | 2026-08-25 |
| 2026-08-21 | S, sale reported on Form 4 | 1,734 | $6.7K | 2026-08-25 |
Enliven Therapeutics, Inc. (IMRA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1869194) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms